WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1999039702) METHOD FOR REGULATING SIZE AND GROWTH OF VASCULARIZED NORMAL TISSUE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1999/039702    International Application No.:    PCT/US1998/022998
Publication Date: 12.08.1999 International Filing Date: 30.10.1998
Chapter 2 Demand Filed:    28.05.1999    
IPC:
A61K 31/00 (2006.01), A61K 31/336 (2006.01), A61K 31/454 (2006.01), A61K 38/39 (2006.01), A61K 38/48 (2006.01)
Applicants: CHILDREN'S MEDICAL CENTER CORPORATION [US/US]; 300 Longwood Avenue Boston, MA 02115 (US).
MASSACHUSETTS INSTITUTE OF TECHNOLOGY [US/US]; 77 Massachusetts Avenue Cambridge, MA 02139 (US)
Inventors: RUPNICK, Maria; (US).
LANGER, Robert, S.; (US).
FOLKMAN, Judah; (US)
Agent: PABST, Patrea, L.; Arnall Golden & Gregory, LLP 2800 One Atlantic Center 1201 West Peachtree Street Atlanta, GA 30309-3450 (US)
Priority Data:
60/064,445 31.10.1997 US
Title (EN) METHOD FOR REGULATING SIZE AND GROWTH OF VASCULARIZED NORMAL TISSUE
(FR) REGULATION DE LA TAILLE ET DE LA CROISSANCE D'UN TISSU NORMAL VASCULARISE
Abstract: front page image
(EN)The present invention is directed generally to the field of treatment of obesity and other disorders characterized by proliferation of normal vascularized tissues, by the administration of effective amount of angiogenesis inhibitors. Angiogenesis inhibitors are administered to regulate normal, non-transformed vascularized tissue size and/or growth by regulating its vascular compartment. Examples of tissues that can be controlled include adipose tissue, intestinal polyps, muscle (including cardiac) tissue, endometrial tissue and prostate tissue. The inhibitor is selected from the group consisting of TNP-470, angiostatin, endostatin, and thalidomide.
(FR)Les données recueillies à propos de la présente invention permettent de penser qu'il est possible d'utiliser les inhibiteurs de l'angiogenèse pour supprimer la croissance d'un tissu endométrial implanté dans la cavité abdominale. La dose de TNP-470 utilisée pour cette étude pilote est le 1/3 de la dose tumorale établie.
Designated States: AU, CA, JP.
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
Publication Language: English (EN)
Filing Language: English (EN)